Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
Sales | 2,377 | 2,840 | 2,575 | 2,485 | 3,029 |
Cost of Goods | 2,008 | 2,500 | 2,276 | 2,221 | 2,673 |
Gross Profit | 369 | 339 | 300 | 264 | 356 |
Operating Expenses | 428 | 962 | 640 | 623 | 994 |
Operating Income | -51 | -123 | -65 | -138 | 35 |
Other Income | -3 | -5 | -2 | -2 | -3 |
Pre-tax Income | -53 | -128 | -67 | -140 | 31 |
Income Tax | 16 | 30 | 10 | -2 | 14 |
Net Income Continuous | -69 | -157 | -77 | -139 | 17 |
Net Income | $-69 | $-157 | $-77 | $-139 | $17 |
EPS Basic Total Ops | -0.01 | -0.02 | -0.03 | 0.00 | 0.00 |
EPS Basic Continuous Ops | 0.00 | -0.02 | -0.01 | 0.00 | 0.00 |
EPS Diluted Total Ops | -0.01 | -0.02 | -0.03 | 0.00 | 0.00 |
EPS Diluted Continuous Ops | 0.00 | -0.02 | -0.01 | 0.00 | 0.00 |
EBITDA(a) | $-26 | $-97 | $-39 | $-111 | $61 |